These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38159023)

  • 41. Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?
    Katsiki N; Perez-Martinez P; Anagnostis P; Mikhailidis DP; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):219-227. PubMed ID: 28669328
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of VEGF-B signaling prevents non-alcoholic fatty liver disease development by targeting lipolysis in the white adipose tissue.
    Falkevall A; Mehlem A; Folestad E; Ning FC; Osorio-Conles Ó; Radmann R; de Hollanda A; Wright SD; Scotney P; Nash A; Eriksson U
    J Hepatol; 2023 May; 78(5):901-913. PubMed ID: 36717026
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phytotherapy as Multi-Hit Therapy to Confront the Multiple Pathophysiology in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Experimental Interventions.
    Ore A; Akinloye OA
    Medicina (Kaunas); 2021 Aug; 57(8):. PubMed ID: 34441028
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map.
    Kumar J; Memon RS; Shahid I; Rizwan T; Zaman M; Menezes RG; Kumar S; Siddiqi TJ; Usman MS
    Dig Liver Dis; 2021 Jan; 53(1):44-51. PubMed ID: 32912770
    [TBL] [Abstract][Full Text] [Related]  

  • 45. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?
    Fan JG; Saibara T; Chitturi S; Kim BI; Sung JJ; Chutaputti A;
    J Gastroenterol Hepatol; 2007 Jun; 22(6):794-800. PubMed ID: 17498218
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [NON-ALCOHOLIC FATTY LIVER DISEASE].
    Bukmir L; Smokrović H; Diminić-Lisica I; Ljubotina A; Popović B
    Acta Med Croatica; 2015 Nov; 69(4):305-10. PubMed ID: 29083841
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Management of Obesity and Nonalcoholic Fatty Liver Disease: A Literature Review.
    Hashem A; Khalouf A; Acosta A
    Semin Liver Dis; 2021 Nov; 41(4):435-447. PubMed ID: 34243193
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Relationship Between Glycaemic Control and Non-Alcoholic Fatty Liver Disease in Nigerian Type 2 Diabetic Patients.
    Afolabi BI; Ibitoye BO; Ikem RT; Omisore AD; Idowu BM; Soyoye DO
    J Natl Med Assoc; 2018 Jun; 110(3):256-264. PubMed ID: 29778128
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies.
    Tomic D; Kemp WW; Roberts SK
    Eur J Gastroenterol Hepatol; 2018 Oct; 30(10):1103-1115. PubMed ID: 30113367
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Non-alcoholic Fatty Liver Disease in Children.
    Muzurović E; Polyzos SA; Mikhailidis DP; Borozan S; Novosel D; Cmiljanić O; Kadić N; Mantzoros CS
    Curr Vasc Pharmacol; 2023; 21(1):4-25. PubMed ID: 36411561
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC.
    Kim H; Lee DS; An TH; Park HJ; Kim WK; Bae KH; Oh KJ
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925827
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Non-obese or lean non-alcoholic fatty liver disease was associated with increased risk of cancer in patients with type 2 diabetes mellitus.
    Chen N; Zhou J; Wang K; Li X; Li Z
    BMJ Open Diabetes Res Care; 2023 Feb; 11(1):. PubMed ID: 36792168
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
    Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
    Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical approaches to non-alcoholic fatty liver disease.
    Schwenger KJ; Allard JP
    World J Gastroenterol; 2014 Feb; 20(7):1712-23. PubMed ID: 24587650
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical Characteristics and Metabolic Profiles of Non-Alcoholic Fatty Liver Disease (NAFLD) in Lean Patients and Their Comparison with Obese and Overweight NAFLD.
    Chakrabarty M; Jha AN; Sharma DJ
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443531
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions.
    Gerges SH; Wahdan SA; Elsherbiny DA; El-Demerdash E
    Life Sci; 2021 Apr; 271():119220. PubMed ID: 33592199
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Nonalcoholic fatty liver disease : Hepatic manifestations of metabolic syndrome].
    Roeb E
    Inn Med (Heidelb); 2023 Apr; 64(4):323-328. PubMed ID: 36580094
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New trends on obesity and NAFLD in Asia.
    Fan JG; Kim SU; Wong VW
    J Hepatol; 2017 Oct; 67(4):862-873. PubMed ID: 28642059
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Non-Alcoholic Fatty Liver Disease and Diabetes: the bad marriage].
    Nascè A; Memaj P; Jornayvaz FR
    Rev Med Suisse; 2023 May; 19(829):1090-1093. PubMed ID: 37260205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.